Novartis Zometa
Executive Summary
Studies are ongoing for bisphosphonate zolendronate in postmenopausal osteoporosis and corticosteroid-induced osteoporosis and are planned in osteogenesis imperfecta, Novartis said. Zometa is receiving FDA fast-track review for tumor-induced hypercalcemia, with a June 21 user-fee goal date (1"The Pink Sheet" Feb. 14, p. 22)